SCHEMBL3689829

SCHEMBL3689829

O=C(O)c1cn(CO)cn1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLA2G4A P47712 1/20 0.40
KDM4E B2RXH2 5/20 0.39
SMYD3 Q9H7B4 1/20 0.35
ADA P00813 1/20 0.34
RBP4 P02753 1/20 0.34
P4HTM Q9NXG6 3/20 0.33
NAPRT Q6XQN6 2/20 0.33
HCAR2 Q8TDS4 2/20 0.33
KDM5A P29375 2/20 0.33
KDM5B Q9UGL1 2/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
P4HA1 P13674 1/20 0.32
MIF P14174 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 1/20 0.32
ACMSD Q8TDX5 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7265607 0.84 PLA2G4A (0.39) PLA2G4AKDM4ESMYD3ADARBP4
SCHEMBL3690823 0.82 PLA2G4A (0.39) PLA2G4AKDM4ESMYD3RBP4P4HTM
SCHEMBL151394 0.82 SMYD3 (0.50) PLA2G4AKDM4ESMYD3RBP4HCAR2
SCHEMBL28309917 0.82 ADA (0.46) SMYD3ADALMNATSHR
SCHEMBL4901656 0.82 PLA2G4A (0.39) PLA2G4AKDM4ESMYD3RBP4P4HTM
SCHEMBL4590582 0.82 PLA2G4A (0.42) PLA2G4AKDM4ESMYD3RBP4P4HTM
SCHEMBL710279 0.79 KDM5A (0.54) PLA2G4AKDM4ESMYD3KDM5AKDM5B
SCHEMBL24035826 0.77 PLA2G4A (0.37) PLA2G4AKDM4ESMYD3ADARBP4
SCHEMBL25235849 0.77 CPB2 (0.47) PLA2G4AKDM4ESMYD3HCAR2KDM5A
SCHEMBL4738757 0.77 PLA2G4A (0.40) PLA2G4AKDM4ESMYD3RBP4KDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015009882-A2 CYANO DERIVATIVES AND THEIR USES THE HAMNER INSTITUTES (US) 2015-01-22 WO disclosed
US-7763607-B2 Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators SOLVAY PHARMACEUTICALS GMBH (DE) 2010-07-27 US disclosed
US-20070254862-A1 Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators SOLVAY PHARMACEUTICALS GMBH (DE) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254862-A1 Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators CNR1, CNR2, KCNJ11 PLA2G4A 872/4885KDM4E 782/4885SMYD3 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.